Regeneron Pharmaceuticals Inc
I · Análisis con IA
En breve
Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].
Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14.3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4.1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].
Regeneron is financially robust with exceptional profitability and zero net debt.
Puntuación Sentinellis
8,9/10
Financieramente sana
Capitalización bursátil
$66,1B
Ingresos (12 meses)
$14,3B
Explicaciones
Cómo leemos estas cifras
Guías en lenguaje sencillo · sin cuenta
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LeerPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LeerAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LeerII · Noticias recientes
Qué movió el precio
6 noticias · ordenadas por relevancia
- Macro2026-05-20
Why Regeneron (REGN) Shares Are Trading Lower Today
Yahoo Finance
- Macro2026-05-19
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
Yahoo Finance
- Macro2026-05-19
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Yahoo Finance
- Macro2026-05-19
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
Yahoo Finance
- Macro2026-05-19
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback
Simply Wall St
- Macro2026-05-18
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Yahoo Finance
Premium · gratis con cualquier cuenta
Pipeline concentration risk: The melanoma trial failure exposed Regeneron's dependence on successful late-stage trials to maintain growth, and further setbacks in other pipeline programs could significantly impact future revenue [Yahoo Finance]
Riesgos
4
Oportunidades
5
Señales de alerta
3
Dirección
10
11 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de Regeneron Pharmaceuticals Inc
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 4 riesgos, 5 oportunidades y 3 señales de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
- Exportación a PDF para leer sin conexión
III · Empresas similares
También te puede interesar
Mismo sector · Salud — o salud financiera comparable
¿La añades a tu lista?